To identify microRNA (miRNA) characteristic of metastatic clear cell renal cell carcinoma (ccRCC) and those indicative of cancer-specific survival (CSS) in nephrectomy and biopsy specimens. We also sought to determine if a miRNA panel could differentiate benign from ccRCC tissue.
Introduction
It's estimated that in 2016 >62 000 new cases of renal cancer were diagnosed, with~64% Stage I or II, indicating localised disease [1, 2] . Current treatment options for these patients include active surveillance, ablative therapies, or surgical extirpation, such as radical or partial nephrectomy. However, despite initial surgical intervention, 20-40% of patients will develop recurrence or metastases [3, 4] . Furthermore, patients with small renal masses treated with nephron-sparing methods, including partial nephrectomy, cryoablation, or radiofrequency ablation are no less likely to develop metastatic progression than those on active surveillance [5] . This suggests that resection alone is not sufficient treatment for biologically aggressive tumours.
The significantly poorer 5-year survival of patients with metastatic disease (<10%) compared to patients with Stage I disease (81%) highlights the importance of accurately identifying patients at risk for disease progression [6] . Several nomograms combine clinical and pathological data to risk stratify patients; however, the accuracy of these models is highly variable [7] [8] [9] . To date, there is no method that can predict with high accuracy which patients will eventually progress to metastatic disease. Hence, the identification of molecular markers predictive of disease progression may augment the accuracy of current nomograms.
MicroRNAs (miRNAs) are involved in the regulation of gene expression through the binding of messenger RNA. They can regulate specific targets or function to control hundreds of genes that can affect cell processes including differentiation, proliferation, and apoptosis [10] . Additionally, miRNAs have been shown to be associated with the pathogenesis of several types of cancer including RCC metastasis [11] .
The ability to use miRNAs as biomarkers to aid in the diagnosis and prognosis of patients with cancer has been demonstrated in a range of malignancies including clear cell RCC (ccRCC), the most common malignant renal cell subtype comprising~80% of cases [12] [13] [14] [15] . Heinzelmann et al. [16] analysed 30 ccRCC samples and developed a miRNA signature distinguishing metastatic from nonmetastatic tumours, as well as those indicative of poor survival. Larger scale studies have since been performed corroborating these results and expanding the candidate list of prognostic miRNA biomarkers for ccRCC [17] [18] [19] [20] .
In the present study, we sought to identify and validate miRNAs that could accurately classify primary ccRCC tumours with a progressive phenotype (i.e. progressing to metastatic disease after resection or metastatic at the time of surgery), and investigate their potential for identifying tumours likely to progress using biopsy specimens. Such a profile could be an adjunct in deciding treatment regimens and improving patient selection for invasive surgery.
Materials and Methods

Tissue Samples
In this Institutional Review Board-approved study, samples were from patients with benign kidney tumours or ccRCC pathology that underwent radical or partial nephrectomy between 1999 and 2008, or core biopsy between 2005 and 2012, at our institution. Patients were excluded if sufficient demographic or clinical data could not be obtained, there was insufficient follow-up (<5 years unless deceased), or if adequate tissue was not available. Samples from patients with ccRCC were grouped based on clinical history: (i) 'local': localised primary tumours, Stage ≤II, with no evidence of progression with a minimum follow-up time of 60 months, (ii) 'synchronous': primary tumour from patients with synchronous metastatic disease at time of surgery, and (iii) 'metachronous': primary tumour from patients who progressed to metachronous metastatic disease after surgery. Samples from the local group were considered 'nonprogressive' and those from the synchronous and metachronous metastatic groups were considered 'progressive'. In addition, for the analysis of non-progressive vs progressive ccRCC, patients with a renal lesion other than ccRCC were excluded, as well as those receiving prior treatment with chemotherapy or targeted agents.
In all, 202 formalin-fixed paraffin-embedded samples were analysed: 156 nephrectomy and 46 biopsy specimens. For nephrectomy samples, the representative tumour block was chosen based on pathological case report review. Most of the metastatic cases had pathologically confirmed metastatic lesions; the remaining cases were in locations not typically biopsied (e.g. bone). In all cases, the clinical evidence was suggestive that the primary tumour used in this study was probably the source of the metastasis. Only one of the metachronous cases in this study had evidence of a contralateral lesion; however, it was discovered 18 months after other metastatic sites. In four cases of metachronous metastatic disease renal vein margins were reported as positive; however, in archived material available for review, these positive renal vein margins represented free floating tumour rather than margin positivity by tumour invading the renal vein wall, and metastasis occurred at least 2 years after primary excision in these patients at sites distant from the renal excision, without evidence of local renal recurrence.
Study Design
Primary analyses were the identification of miRNAs capable of discriminating benign renal masses from ccRCC, as well as discriminating non-progressive from progressive ccRCC. Secondary analyses investigated the association of miRNA profiles with cancer-specific survival (CSS). Analyses were initially performed with nephrectomy specimens, and miRNAs of interest were subsequently tested using core biopsy specimens (from here on simply referred to as 'biopsy specimens'). Testing was performed in three phases (Fig. 1) . For the initial screening phase three pools of nephrectomy samples were profiled using miRNA microarrays: (i) local (n = 7), (ii) synchronous metastatic (n = 7), and (iii) metachronous metastatic (n = 7).
Subsequently, a selection of differentially expressed miRNAs was tested in the second phase on individual nephrectomy specimens in two separate analyses: one investigated ccRCC and benign kidney tumours and the other investigated nonprogressive and progressive ccRCC. In an effort to develop a diagnostic model, samples were randomly assigned to either training sets to verify miRNAs with differential expression, or validation sets to access the diagnostic capability of the training set miRNA signature. For the analysis of ccRCC and benign nephrectomies there were 98 specimens in the training set (benign = 50, ccRCC = 48), and 58 in the validation set (benign = 28, ccRCC = 30). For the analysis of progressive ccRCC there were 50 nephrectomy specimens in the training set (non-progressive = 20, progressive = 30), and 28 in the validation set (non-progressive = 12, progressive = 16). In the third phase, miRNAs were evaluated in biopsy specimens: benign vs ccRCC (n = 25 and 21, respectively) and nonprogressive vs progressive ccRCC (n = 10 and 11, respectively). CSS was investigated in all of the ccRCC cases.
MiRNA Isolation
Total RNA was isolated using the RecoverAll â Total Nucleic Acid Isolation Kit (Ambion, Foster City, CA, USA) according to the manufacturer's instructions using four sequential 20-lm sections per sample.
Screening Phase Microarray Analysis
Pooled samples of total RNA were analysed using miRCURY TM Screening : microarray analysis of 2019 miRNA comparing three groups of pooled ccRCC nephrectomy specimens (7 local, 7 synchronous metastatic, and 7 metachronous metastatic) miRNA were selected from those with ≥1.75-fold difference in expression on microarray analysis and/or those previously reported to be associated with ccRCC.
Nephrectomy sample analysis: qRT-PCR of 9 miRNA on 156 specimens (n = 78 benign, n = 78 ccRCC)
Training set statistical analysis: Four miRNA model developed using logistic regression with 98 nephrectomy specimens (n = 50 benign, n = 48 ccRCC)
Model validation: 58 separate nephrectomy samples (n = 28 benign, n = 30 ccRCC) were classified using the 4-miR training set model 
Real-Time PCR Analysis
A selection of differentially expressed miRNA identified in the microarray experiment, as well as others identified through literature review of analogous miRNA studies in ccRCC, were validated by quantitative reverse transcription (qRT-PCR). Analysis was performed using individual samples according to the manufacturers' protocols (Exiqon). In 20 lL universal reverse transcription reactions, 3.5 ng of total RNA per sample was used; subsequently 30 pg of cDNA was used in each 20 lL qRT-PCR reaction, tested in triplicate. A twostep process was used for normalisation: first an equal quantity of RNA was used for each sample, and second, candidate miRNAs for normalising were screened using NormFinder© [22] .
Statistical Analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS â version 23; SPSS Inc., IBM Corp., Armonk, NY, USA). qRT-PCR expression levels of miRNAs were normalised to the insignificant control miR125b-5p detected in all samples and quantified as x = 2 ÀDC t . The continuous variables of miRNA expression, body mass index (BMI), and age (at time of surgery or biopsy) were compared between groups using a two-tailed independent sample Mann-Whitney U-test or the Kruskal-Wallis test followed by the Mann-Whitney U-test for between group comparisons, as appropriate. The pathological variables of grade and stage were dichotomised: Grade 1 + 2 vs 3 + 4 and Stage I + II vs III + IV. Categorical variables were analysed using Chi-squared tests. To determine whether the miRNAs were independently predictive of status (benign vs ccRCC or non-progressive vs progressive ccRCC), we used logistic regression modelling performed using forward selection on likelihood ratio (P < 0.15 for entry and P > 0.20 for removal, as described by Hosmer et al. [23] ). Diagnostic performance was evaluated by the area under the curve (AUC) for receiver operating characteristic (ROC) curves. For CSS analysis continuous variables were dichotomised (e.g. low vs high expression) by constructing ROC curves discriminating patients by survival status, and then using Youden's Index [(sensitivity + specificity) -1)] to determine optimal threshold levels [24] . Cox's proportional hazard modelling (single and multivariable) was used to estimate the hazard ratio (HR) of death, and survival estimates were computed using the Kaplan-Meier method comparing groups with the log-rank test. Patients alive at the time of analysis or lost to follow-up were censored using the last date of followup. Survival and follow-up times were calculated from the date of surgery or biopsy. A P < 0.05 was considered statistically significant.
Results
Demographics
Nephrectomy specimens were obtained from 78 patients with benign kidney disease of varying pathologies and 78 patients with ccRCC (Table 1) . Within the ccRCC nephrectomy group, 25 patients had metastatic disease at the time of surgery (synchronous metastases); 21 patients had local disease at the time of surgery, which later progressed to metastatic disease (metachronous metastases); and 32 patients had local disease, which did not progress. The median followup time, for censored patients with local, metachronous metastatic, and synchronous metastatic disease was 110, 90, and 76 months, respectively. The minimum follow-up time for those with local disease was 62 months. Biopsy specimens were obtained from 46 patients: 25 benign and 21 with ccRCC ( Table 1 ). The most common pathology in both benign groups was oncocytoma, whereas the remaining benign specimens were represented by non-neoplastic inflammatory, fibrotic, or cystic mass-forming lesions. Within the ccRCC biopsies, seven patients had synchronous metastatic disease, four were metachronous metastatic, and 10 did not progress. The median follow-up time for biopsy samples from censored patients with local disease was 86 and 45 months for those with metachronous metastatic disease. All biopsy cases from patients with synchronous metastatic disease died within the follow-up period. The minimum follow-up time for those with local disease was 60 months, with the exception of one patient who died at 52 months from an unrelated cause.
Initial Screening via miRNA Microarray
There were 665 miRNAs detected across all samples and 20 miRNAs were differentially expressed by at least AE1.75-fold. Hierarchical cluster analysis (Fig. 2 ) of these top 20 miRNA resulted in a grouping of the synchronous and metachronous metastatic pools separate from the local pool.
Classification of Benign and ccRCC Samples
Nephrectomy specimens
Within the training set of 98 samples, the groups did not differ for age or gender (Table 2A) . Nine miRNAs were analysed by qRT-PCR. Differential expression between the benign and ccRCC groups was identified for six of these miRNAs (P < 0.05), where all but one of these, miR-142-5p, showed decreased expression in cancers compared to benign specimens (Table 3A) . Using the six significant miRNA training samples data, stepwise logistic regression analysis was performed. Four miRNAs (10a-5p, 10b-5p, 106a-5p, and 142-5p; Fig. 3A) were retained in the model resulting in a sensitivity of 91.7%, a specificity of 94%, a positive predictive value (PPV) of 93.6%, and a negative predictive value (NPV) of 92.2%. ROC analysis of the four miRNA classifier estimated an AUC of 0.992 (95% CI 0.981-1.0; Fig. 4A ). The formula for this classifier was as follows: logit(P) = 2.687 -75.78 9 10a-5p + 19.903 9 10b-5p -74.908 9 106a-5p + 136.471 9 142-5p. We validated the model performance of this miRNA panel with 58 additional nephrectomy specimens. This resulted in a sensitivity of 86.7%, a specificity of 92.9%, a PPV of 92.9%, a NPV of 86.7%, and an AUC of 0.930 (95% CI 0.858-1.0; Fig. 4B ) for detecting ccRCC.
Biopsy specimens
The four miRNAs retained in the training analysis were subsequently evaluated in 46 biopsy specimens (Table 3A) . Similarly to the nephrectomy specimen results, decreased levels of expression were seen for miR-10a-5p and miR-10b-5p, as well as increased expression for miR-142-5p in biopsies from patients with ccRCC compared to benign specimens. However, these differences were only significant for miR-10b-5p and miR-142-5p. Using the two significant miRNAs, stepwise logistic regression analysis was performed. Both miRNAs were retained in the model resulting in 76.2% sensitivity, 80% specificity, a PPV of 76.2%, a NPV of 80%, and an AUC of 0.770 (95% CI 0.628-0.911; Fig. 4C ) for detecting ccRCC.
Association of miRNA with a Progressive Phenotype
Nephrectomy specimens
To investigate the association of miRNA with a progressive ccRCC phenotype, the progressive nephrectomy samples were compared to the non-progressive samples. MiRNA expression was analysed in a training group of 50 samples. This revealed that the expression of miR-10a-5p, -10b-5p and -223-3p were significantly different between the groups (Table 3B) . Expression levels of miR-10a-5p and miR-10b-5p were decreased and miR-223-3p was increased in the progressive samples (Fig. 3B) . Additionally, the variables of age, grade, and stage were significantly different between the groups (Table 2B) . Stepwise logistic regression analysis including these six significant variables retained grade, stage, and miR-10a-5p resulting in 93.3% sensitivity, 95% specificity, a PPV of 96.6%, a NPV of 90.5%, and an AUC of 0.995 (95% CI 0.983-1.0; Fig. S1A ) for discriminating progressive ccRCC. Stepwise logistic regression analysis of only age, grade, and stage retained grade and stage and resulted in a 96.7% sensitivity, 75% specificity, a PPV of 85.3%, a NPV of 93.8%, and an AUC of 0.942 (95% CI 0.880-1.0; Fig. S1B ).
The variables of age and miRNA expression were evaluated exclusive of grade and stage in the interest of also investigating a classifier in biopsy samples where pathological determination of grade and stage are not able to be accessed.
Stepwise logistic regression analysis of the training specimens with only age, miR-10a-5p, miR-10b-5p, and miR-223-3p retained miR-10a-5p and -223-3p resulting in 86.7% sensitivity, 75% specificity, a PPV of 83.9%, a NPV of 78.9%, and an AUC of 0.895 (95% CI 0.808-0.982; Fig. 4D ). The formula of this classifier was: logit(P) = 0.617-253.296 9 Fig. 4E ) for detecting progressive ccRCC.
Biopsy specimens
Expression of the same three miRNA was evaluated in 21 ccRCC biopsy specimens (Table 3B ). The median expression levels in progressive samples were lower for miR-10b-5p and miR-10a-5p, and higher for miR-223-3p, in concordance with the results seen in the nephrectomy specimens. However, only miR-10b-5p was significant. In the interest of exploring the potential of using biopsy samples in detecting progressive ccRCC, a stepwise logistic regression analysis was performed; considering the limited sample size, only the two most differentially expressed miRNA were examined (miR-10b-5p and -223-3p) to avoid over-fitting the model. Both variables were retained resulting in 90.9% sensitivity, 80% specificity, a PPV of 83.3%, a NPV of 88.9%, and an AUC of 0.845 (95% CI 0.669-1.0; Fig. 4F ).
Correlation of miRNA Expression Levels with CSS
Nephrectomy specimens CSS estimates were calculated using the dichotomised variables of age, BMI, grade, stage, miR-10a-5p, miR-10b-5p, and miR-223-3p for all ccRCC nephrectomy cases (n = 78). In Kaplan-Meier analyses, higher BMI, lower grade, and lower stage were significantly associated with survival (P < 0.001; Fig. S2 ). Higher expression levels of miR-10a-5p and miR-10b-5p and a lower expression level of miR-223-3p were significantly associated with survival (P < 0.001 Fig. 5A ,B, and P = 0.003 Fig. 5C , respectively), and the median survival times were not reached. The median survival times associated with lower expression levels of miR-10a-5p and miR-10b-5p and a higher expression level of miR-223-3p were 37, 35, and 57 months, respectively.
Restricting the Kaplan-Meier analyses to only the metastatic nephrectomy specimens (metachronous and synchronous, n = 46), higher expression levels of miR-10a-5p and miR-10b-5p were significantly associated with survival (P = 0.037 and P = 0.031, respectively; Fig. S3A,B) . The median survival times associated with higher vs lower miR-10a-5p expression were 100 vs 34 months, respectively, and the median survival times associated with higher vs lower miR-10b-5p expression were 73 vs 23 months, respectively.
Univariable Cox proportional hazards analyses performed to estimate the hazard of death revealed a significant correlation with death for a lower BMI, high grade, high stage, low miR10a-5p, low miR-10b-5p, and high miR-223-3p. On multivariable analysis, BMI, stage, miR-10a-5p, and miR-223-3p expression remained independent predictors of death (HR 0.23, 95% CI 0.08-0.064; HR 2.56, 95% CI 1.11-5.92; HR 3.28, 95% CI 1.08-9.90; and HR 3.51, 95% CI 1.60-7.69; respectively; Table 4 ). Expression levels within the progressive ccRCC training set (n = 20 nonprogressive and n = 30 progressive [n = 13 metachronous and n = 17 synchronous]) of the three miRNAs differentially expressed in progressive ccRCC. *P < 0.05; **P < 0.01; ***P < 0.001; NS, non-significant. Biopsy specimens CSS estimates were investigated in all of the ccRCC biopsy specimens (n = 21) and Kaplan-Meier analyses revealed similar findings to that in the nephrectomy specimens. A higher expression level of miR-10b-5p and a lower expression level of miR-223-3p were significantly associated with survival (P = 0.027, Fig. 5D ; and P = 0.013, Fig. 5E ; respectively). However, no significant association with survival was seen for age (P = 0.473), BMI (P = 0.050), or miR-10a-5p (P = 0.062).
Univariable Cox proportional hazards analyses were performed for age, BMI, miR-10a-5p, miR-10b-5p, and miR-223-3p revealing a significant correlation with death for low miR-10b-5p and high miR-223-3p. These two variables were entered into a multivariable analysis and both remained independent predictors of death (miR-10b-5p HR 5.85, 95% CI 1.30-26.33 and HR 6.75, 95% CI 1.54-29.56; Table 4 ).
Discussion
In the present study, a classifier consisting of miRNAs 10a-5p, 10b-5p, 106a-5p, and 142-5p discriminated benign mass lesions from ccRCC with a high degree of sensitivity and specificity in two nephrectomy sample sets. In addition, miRNAs 10b-5p and 142-5p detected ccRCC in an independent group of biopsy specimens. While other reports [18, 25, 26] have described differential miRNA expression profiles between benign and ccRCC specimens, the present study is unique in that the breadth of benign lesions mirrors clinically detected neoplastic and non-neoplastic massforming lesions and subsequent inclusion of core biopsy samples. A study by Silva-Santos et al. [18] used miRNA to discriminate different types of kidney tumours and showed the feasibility of applying a miRNA signature when small amounts of tissue were obtained using fresh-frozen ex vivo fine-needle aspiration biopsies. To our knowledge, our present study is the first to investigate miRNA biomarkers in core biopsy material that was processed for pathological analysis and investigated markers associated with aggressive ccRCC and CSS.
Combining clinical and molecular data through an integrative model has the potential to make novel nomograms predictive of progressive ccRCC with better accuracy, than either variable set alone. The model including grade, stage, and miR-10a-5p had a high PPV and NPV. Only using miR-10a-5p and -223-3p still achieved a high PPV and NPV for two groups of nephrectomy specimens. In addition, the potential of miRNA to detect progressive ccRCC was shown with a limited set of biopsy samples using miR-10b-5p and -223-3p. While these results are preliminary, the possible implications are noteworthy.
In addition, we show that miRNA expression profiles are also correlated with CSS. Our present analysis found that for nephrectomy specimens, high levels of miR-10a-5p, high levels of miR-10b-5p, and low levels of miR-223-3p were associated with improved CSS, and in multivariable analysis the levels of miR-10a-5p and miR-223-3p were independently associated with a hazard of death from ccRCC. Similar findings extended to the analysis of biopsy specimens, where miR-10b-5p and miR-223-3p remained independently associated with a hazard of death from ccRCC. Three of the clinical variables analysed for patients with nephrectomy specimens were also significantly associated with CSS. As expected, high grade and stage were linked with poorer survival and interestingly, lower BMI was as well. This is consistent with the 'obesity paradox', where CSS increases with BMI in patients with ccRCC [27] .
Although the sample size of the biopsy cohort is limited, the correlation of miR-10b-5p and 223-3p expression with aggressiveness and poor survival was compelling. With the increasing trend to biopsy renal masses, there is an opportunity to incorporate biomarker analysis at an early stage in an effort to better stratify patients and clarify treatment options.
While most of our present data were consistent between the nephrectomy and biopsy specimens, the lack of congruency for some miRNAs may be due to differences in the collection, preservation, and method of sampling. Small biopsies may show differing rates of miRNA preservation vs nephrectomy specimens. Biopsies were collected in saline or alcohol-based media, to facilitate retrieval of small, fragmented tissue cores via centrifugation and cell block preparation. These biopsies were then formalin-fixed after the cell block was created, while nephrectomy specimens were placed in formalin immediately after resection. An additional variable is the rate of tissue fixation. Because formalin penetrates larger tissues slowly, the interval before fixation may be longer with nephrectomy specimens, which may impact miRNA preservation and recovery. In core biopsies, the sequential fixation in an alcohol-based medium, followed by formalin fixation, may impact miRNA measurements.
Several miRNAs in our present panels were also detected in other studies comparing RCC. Many studies have shown that miR-10b-5p is down-regulated in ccRCC samples [16, 17, 19, [28] [29] [30] [31] , and this correlated with poor survival as well [16, 19] . We also observed decreased expression of miR10b-5p in progressive ccRCC, which correlated with poor CSS in nephrectomy and biopsy specimens. MiRNA-10b-5p has been reported as being up-or down-regulated in several cancers [32] . It is often associated with poor survival and all reports in ccRCC, including the present study, are with decreased expression. Specific miRNAs associated with pro-and anti-metastasis effects have been termed 'metastamirs'. The first metastamir was reported by Ma et al. [33] in 2007, when they showed that tumour invasion and metastasis where initiated by miR10b-5p in breast cancer. Wotschofsky et al. [34] identified a panel of metastamirs in ccRCC that also included miR-10b-5p. In contrast to the elevated levels of miR-10b-5p in metastatic breast cancer, miR-10b-5p expression levels were down-regulated in metastatic ccRCC samples [16, 34] . In the present study, reduced miR-10b-5p was also seen in primary tumours from patients whom were either metastatic at diagnosis or developed subsequently to resection, reiterating the fact that the same miRNAs can have opposite effects in different cancer types.
Additional studies of RCC have reported miRNA expression consistent with the data presented here. Tsukigi et al. [35] found decreased miR-199a-5p expression in 59% of RCCs. They identified miR-199a-5p as a negative regulator of Glycogen synthase kinase 3b (GSK-3b), and suggest reexpression of pre-miR-199a-5p as a new potential treatment of RCCs. Our present findings of lower miR-199a-5p levels in the ccRCC samples as compared to renal benign tissue concur. M€ uller and Nowak [36] reported lower levels of miR-106a-5p and higher levels of miR-142-5p in ccRCC samples compared to normal parenchyma; this correlates with the differences we observed comparing ccRCC and benign lesions. Similar to findings presented here, Gowrishankar et al. [31] observed decreased expression of miR-10a-5p in ccRCC. In the present study, this was associated with decrease CSS, and is consistent with data reported by Heinzelmann et al. [16] . In addition, Gowrishankar et al. [31] reported higher levels of miR-223-3p in ccRCC samples with higher grade and stage, consistent with our present finding of higher miR-223-3p in progressive samples.
Further study into the role of metastamirs in the development of metastatic RCC could generate molecular assays with the potential to improve patient selection for aggressive treatment. When combined with clinical and pathological data, such an assay could help with risk stratification and alter treatment paradigms, as limited metastatic burden increases the likelihood of a favourable response to treatment [37] .
While the miRNA classifiers in the present study exhibited high sensitivity and specificity and were associated with survival, there are limitations to this work. Although each case was reviewed to select the most representative block for analysis the tissues were not macro-dissected. In some cases this resulted in the inclusion of portions of extraneous tissue (e.g. fibrotic or necrotic) that could confound the results. In addition, adjustments for multiple comparisons were not performed. We chose not to adjust knowing this could increase the likelihood of false positives, rather than adjust and risk missing a potentially informative biomarker. Therefore, before the transition of miRNA from bench to bedside, larger multi-institutional prospective studies are needed to confirm these results and establish a definitive panel of miRNA biomarkers to detect disease presence, biological aggressiveness, and prognosis in ccRCC.
Although improvements in treatment of metastatic RCC have been made, the mortality rate has not changed and identification of patients at risk of disease progression remains challenging. The evaluation of patients with small renal masses (<4 cm) may include percutaneous biopsy in an effort to develop an appropriate treatment plan. Although adjuvant therapy is not currently approved for use in patients with clinically localised ccRCC, if there was an accurate method to determine which patients will have disease progression, systemic therapy with targeted molecular agents to help prevent the development of metastatic disease may be warranted. Eventually, the goal will be to develop a miRNA profile predictive of metastatic progression to help guide prognosis and provide more accurate risk stratifications to patients, and help guide appropriate follow-up regimens on an individualised basis. The application of our present data showing specific miRNAs indicative of tumour aggressiveness could potentially be applied to renal biopsy specimens and aid in a more reliable assignment of patients to an active surveillance protocol or treatment.
